Advertisement

Mathematical determination of some oncological parameters and their therapeutic implications in dogs

  • Saganuwan Alhaji SaganuwanEmail author
Original Article
  • 6 Downloads

Abstract

Cancer is a serious life-threatening disease with increased morbidity and mortality in dogs. A number of cancers are diagnosed after metastasis has taken place when therapeutic intervention would have been useless. In view of this, mammary gland tumors and adenocarcinoma of the lungs were calculated using some established and revised formulas. The reported fundamental parameters were calculated using macroscopy. But the mathematical oncological analysis revealed that tumor doubling time (82.1–123.1 days) of adenocarcinoma of the lung was lower than that of complex mammary adenoma (101.3–151.9 days), complex carcinoma of the lung (215.5–323.2 days), and benign mammary gland tumor (810–1215 days), respectively, suggesting that adenocarcinoma of the lung proliferates faster than the remaining cancers. Cancer cells per year for adenocarcinoma (1.21 × 108), benign mammary gland tumor (1.35 × 109), complex mammary adenoma (1.4–3.3 × 108), and complex carcinoma of the lung (3.4 × 108) with benign mammary gland tumor metastasized and others were about to metastasize. Therefore, the formulas can be used in estimation of some oncological parameters such as tumor volume, tumor weight, and tumor doubling time. All the investigated tumors can be managed chemotherapeutically if detected early enough. However, adenocarcinoma of the lung may be proven very difficult to treat because of low tumor doubling, doubling time followed by complex mammary adenoma, and complex carcinoma of the lung. Hence, oncological parameters could serve as indices of successful therapeutic interventions.

Keywords

Cancer Parameters Mathematics Treatment intervention 

Notes

Compliance with ethical standards

Conflict of interest

The author declares that there is no conflict of interest

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. Abdallah BK, Rashid NG, Tawfiq SA (2018) Demographic features of neuroblastoma in Iraq- Kurdistan region-Sulaimani. Iraqi J Hematol 7:62–66Google Scholar
  2. Adams MP, Koch RW (2010) Pharmacology connections to nursing practice. Pearson, New Jersey, p 1526Google Scholar
  3. Albert RE, Benjamin SA, Shukla R (1994) Life span and cancer mortality in the beagle dog and humans. Mech Aging Dev 74(3):147–159CrossRefGoogle Scholar
  4. Altman DG (1992) Analysis of survival times in: practical statistics for medical research. Chapman and Hall, London, pp 365–393Google Scholar
  5. Anisimov VN (1987) Carcinogenesis and aging. Vol. 1 & 2. CRC Press, Boca RatonGoogle Scholar
  6. Anisimov VN (2002) The relationship between aging and carcinogesis: a critical appraisal. Crit Rev Oncol Hematol 45:277–304CrossRefGoogle Scholar
  7. Baade P, Youlden DR, Andersson TML, Youl PH, Kimlin MG, Aitken JF, Biggar RJ (2015) Estimating the change in life expectancy after a diagnosis of cancer among the Australian population. BMJ Open 5:1–7CrossRefGoogle Scholar
  8. Baker MJ, Gazi E, Brown MD, Shanks JH, Gardner P, Clarke NW (2008) FTIR – based spectroscopic analysis in the identification of clinically aggressive prostate. Cancer 99:1854–1866Google Scholar
  9. Bellisola G, Sorio C (2012) Infrared spectroscopy and microscopy in cancer research and diagnosis. Am J Cancer Res 2(1):1–21PubMedGoogle Scholar
  10. Bradley NL, Wiseman SM (2017) Papillary thyroid microcarcinoma: the significance of high risk features. BMC Cancer 17:1–5CrossRefGoogle Scholar
  11. Buffenstein R (2008) Distinct tumor suppressor mechanisms evolve in rodent species that differ in size and lifespan. Aging Cell 7:813–823CrossRefGoogle Scholar
  12. Burek JD, Hollander CF (1977) Incidence patterns of spontaneous tumors in BN/Bi rats. J Natl Cancer Inst 58:99–105PubMedCrossRefGoogle Scholar
  13. Campisi J (2005) Senescent cells, tumor suppression and organizational aging: good citizens, bad neighbors. Cell 120:513–522PubMedCrossRefGoogle Scholar
  14. Capocaccia R, Gatta G, Maso LD (2015) Life expectancy of colon, breast and testicular cancer patients: an analysis of US-SEER population based data. Ann Oncol 26:1263–1268PubMedCrossRefGoogle Scholar
  15. Chauviere AH, Hatzikirou H, Lowengrub JS, Frieboes HB, Thompson AM, Cristini V (2011) Mathematical oncology: how are the mathematical and physical sciences contributing to the war on breast cancer? Curr Breast Cancer Rep 2(3):121–129CrossRefGoogle Scholar
  16. Cizkova J, Cervinkova M (2015) Celiac disease and cancer-are there potential links? is the vigilance of immune system in celiac disease a doubleedged sword? Int J Celiac Dis 3(4):148–150CrossRefGoogle Scholar
  17. Coleman MP, Quaresma N, Berrino E, Lutz JM, Angelis RD, Capocaccia R, Baili P, Rachet B, Gatta, Hakulonen T, Micheli A, Sagt M, Weir HK, Edwood JM, Tsukuma H, Koifman SA, Azevedoe SG, Francisi S, Santaquilari W, Verderchia A, Storm HH, Young JL, Concord Working Group (2008) Cancer survival in five continents: a worldwide population-based study. Lancet Oncol 9:730–756PubMedCrossRefGoogle Scholar
  18. Cummings BS, Wills LP, Schnellmann RG (2004) Measurement of cell death in mammalian cells. Curr Prot Pharmacol.  https://doi.org/10.1002/0471141755.ph1208s25
  19. De Luca AC, Dholakia K, Mazilu M (2015) Modulated Raman spectroscopy for enhanced cancer diagnosis at the cellular level. Sensors 15:13680–13704PubMedCrossRefGoogle Scholar
  20. Dix D, Cohen P, Flannery J (1980) On the role of aging in cancer incidence. J Theor Biol 83:163–173PubMedCrossRefGoogle Scholar
  21. Dorm C-R (1967) The epidemiology of cancer in animals. California Med 107(6):481–489Google Scholar
  22. Dubray B, Henry-Amar M, Meenwaldt JH, Noordijk EM, Dixon DO, Cosset JM, Thames HD (1995) Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiother Oncol 36(3):211–217PubMedCrossRefGoogle Scholar
  23. Ferlay J, Shin HR, Bray E, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008. Int J Cancer 127:2893–2917CrossRefGoogle Scholar
  24. Fornvik D, Lang K, Andersson I, Dustler M, Borquist S, Timberg P (2016) Estimates of breast cancer growth rate from mammograms and its relation to tumor characteristics. Radiat Prot Dosim 169(1–4):151–157CrossRefGoogle Scholar
  25. Forrest LJ, Dodge RK, Page RL, Heidner GL, Mc Entee MC, Novotney CA, Thrall DE (1992) Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with osteosarcoma. J Nuclear Med 33(8):1542–1547Google Scholar
  26. Friberg S, Nystrom A (2015) Cancer metastasis: early dissemination and late recurrences. Cancer Growth Metastasis 8:43–49PubMedPubMedCentralCrossRefGoogle Scholar
  27. Goel MK, Khanna P, Kishore J (2010) Understanding analysis: Kaplan-Meier estimate. Int J Ayurveda Res 1(4):274–278PubMedPubMedCentralCrossRefGoogle Scholar
  28. Gorbunova V, Saluanov A, Zhang Z, Gladyshev VN and Vijg J (2014) Comparative genetics of longevity and cancer: insights from long-lived rodentsGoogle Scholar
  29. Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CY, Wang WP, Li Z and Zhang Li J (2012) The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neo-adjuvant chemotherapyGoogle Scholar
  30. Hafen E, Stocker H (2003) How are the sizes of cells, organs and bodies controlled? PLoS Biol 1(3):319–323CrossRefGoogle Scholar
  31. Han JH, Kim KS, Kim JH (2016) Mammary gland tumors in three male dogs. Kor J Vet Res 56(4):292–232Google Scholar
  32. Honda O, Nakamura H (2009) Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer 66(2):211–217PubMedCrossRefGoogle Scholar
  33. Kanashiki M, Tomizawa T, Yamuguchi I, Kurishona K, Hizawa N, Ishikawa H, Kagohashi K, Satih H (2012) Volume doubling time of lung cancers detected in a chest radiograph mass screening program: comparison with CT screening. Oncol Lett 4(3):513–516PubMedPubMedCentralCrossRefGoogle Scholar
  34. Kor YG, Saeedan M, Sobei MSB (2017) Breast cancer arising from a suspected fibroadenoma during pregnancy: a case report and review of literature. J Cancer Sci Ther 9(8):589–592Google Scholar
  35. Kotwal AA, Mohile SG, Dale W (2012) Remaining life expectancy measurement and PSA screening of older men. J Geriatr Oncol 3(3):196–204PubMedPubMedCentralCrossRefGoogle Scholar
  36. Kristiansen VM, Devvi S, Horsberg TE, Jonasdotthir TJ, Moe L, Berlinger B, Lindkaer-Jensen S, Larsen S (2015) Tolerability and pharmacokinetic profile of a novel benzene-polycarboxylic acids complex with cis-diammineplatinum (11) dichloride in dogs with malignant mammary tumors. Vet Comp Oncol 15(1):118–132PubMedCrossRefGoogle Scholar
  37. Kuang Y, Nagy JD, Eikenberry SE (2016) Introduction to mathematical oncology. CRC Press, Boca RatonGoogle Scholar
  38. Laird, A.K. (1965). British journal of Cancer 19: 278,Google Scholar
  39. Lipinan R, Galecki A, Burke DT, Miller RA (2004) Genetic loci that influence cause of death in a heterogenous mouse stock. J Gentorol A Biol Sci Med Sci 59:977–983CrossRefGoogle Scholar
  40. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) Molecular cell biology. W.H. Freeman & Co., New YorkGoogle Scholar
  41. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P (2007) Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 67(8):3493–3987CrossRefGoogle Scholar
  42. Mehrotra R, Ray B, Chaturvedi H (2016) Biochemical characterization of lung cancer tissue: a spectroscopic investigation. J Cancer Clin Oncol 2(1):1–8Google Scholar
  43. Michor F, Beal K (2015) Improving cancer treatment via mathematical modelling: surmounting the challenges is worth the effort. Cell 163:1059–1063PubMedPubMedCentralCrossRefGoogle Scholar
  44. Pacholczyk B, Fabianska A, Kusinka R, Potemski P, Kordek R, Jankowski S (2012) Analysis of cancer tissues by means of spectroscopic methods. Contemp Oncol (Pozn) 16(4):290–294Google Scholar
  45. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37:4–66CrossRefGoogle Scholar
  46. Pugnetti G (1980) Simon and Schuster’s Guide to Dogs. Simon and Schuster Inc., New York, p 447Google Scholar
  47. Rai T, Kuroishi TY, Kurita Y, Naruke T, Kaneko M (1994) Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Jpn J Clin Oncol 24(4):199–204Google Scholar
  48. Rajaraman R et al (2007) Telomere uncapping in progenitor cells with critical telomere shortening is coupled to S-phase progression in vivo. PNAS 104(45):17747–17752PubMedCrossRefGoogle Scholar
  49. Ramos IRM, Malkin A, Lyng FM (2015) Current advances in the application of raman spectroscopy for molecular diagnosis of cervical cancer. Biomed Res Int 12561242:1–9CrossRefGoogle Scholar
  50. Rowell JL, McCarthy DO, Alvarez CE (2011) Dog models of naturally occurring cancer. Trends Mol Med 17:380–388PubMedPubMedCentralCrossRefGoogle Scholar
  51. Rich JT, Neely TG, Paniello RC, Voelker CCJ, Nussenbaum B, Wang EC (2010) A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 143(3):331–336PubMedPubMedCentralCrossRefGoogle Scholar
  52. Ryu EB, Change JM, Seo M, Kim SA, Lim JH, Moon WK (2014) Tumor volume doubling time of molecular breast cancer cell types assessed by serial ultrasound. Eur Radiol 24(9):2227–2235PubMedCrossRefGoogle Scholar
  53. Saganuwan SA (2017) Derivation of a unique body surface area (bsa) formula for calculation of relatively safe doses of dog and human anticancer drugs. J Cancer Sci Ther 9(10):690–704CrossRefGoogle Scholar
  54. Saganuwan SA (2018). Relationship between body surface areas and encephalization quotient in chemotherapy of brain cancers: the functions of four modified formulas. Twelfth World Cancer Congress, July 23-25; Moscow, Russia 3: 4Google Scholar
  55. Saganuwan SA, Ndakotsu AM (2015) Standardization and scoring of the body surface area (bsa) formulas for calculation of the doses of anticancer agents for cancer patients from the north-western Nigeria. J Cancer Sci Ther 7(1):012–018CrossRefGoogle Scholar
  56. Sannachi L, Tadayyon H, Sadeghi-Naini A, Tan W, Gandhi S, Wright F, Oelze M, Czarnota G (2015) Non-invasive evaluation of breast cancer response to chemotherapy using quantitative ultrasonic backscatter parameters. Med Image Anal 20:224–236PubMedCrossRefGoogle Scholar
  57. Seluanov A, Chen Z, Hine C, Sasahara THC, Ribeiro AACM, Catania KC, Presgraves DC, Gorbunova V (2007) Telomerase activity coevolves with body mass not lifespan. Ageing Cell 6:45–52CrossRefGoogle Scholar
  58. Skipper HE, Perry S (1970) Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. 30(6):1883–1897Google Scholar
  59. Soerjomataram L, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:1840–1850PubMedCrossRefGoogle Scholar
  60. Stadtlander CTKH (2017) Introduction to mathematical oncology 10(1):501–505Google Scholar
  61. Tacutu R, Craig T, Budovsky A, Wuttke D, Lehmann G, Taranukha D, Costa J, Fraifeld VE, de Magalhaes JP (2013) Human ageing genomic resources: integrated databases and tools for the biology and genetics of ageing. Nucleic Acids Res 41:1–7CrossRefGoogle Scholar
  62. Tait SWG, Green DR (2008) Caspace independent cell death: leaving the set without the final cut. Oncogene 27(50):6452–6461Google Scholar
  63. Tubiana M, Pejovic MH, Koscielny S, Chavaudra N, Malaise E (1989) Growth rate, kinetics of tumor cell proliferation and long- term outcome in human breast cancer. Int J Cancer 44(1):17–22Google Scholar
  64. Walker, Whittlesea C (2012) Clinical pharmacy and therapeutics, 5th edn. Churchill Livingstone, Elsevier, Philadelphia, p 983Google Scholar
  65. Werahera PN, Glide M, LA Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T(2011) Proliferative tumor doubling times of prostatic carcinoma. Prost Cancer. ID301850Google Scholar
  66. Wilson DO, Ryan A, Fuhrman C, Schuchert M, Sairo S, Siegfried JM, Weissfeld J (2012) Doubling times and CT screen-detected lung cancers in the Pittsburg lung screening study. Am J Crit Care Med 185(1):85–89CrossRefGoogle Scholar
  67. Zar JH (2008) Biostatistical analysis, 4th edn. Pearson Education, Inc., New Delhi, p 663Google Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Veterinary Physiology, Pharmacology and BiochemistryUniversity of AgricultureMakurdiNigeria

Personalised recommendations